VACCINE COMPOSITIONS OF M2e, HA0 AND BM2 MULTIPLE ANTIGENIC PEPTIDES
The present disclosure generally relates to a composition comprising one or more peptides selected from influenza virus antigenic peptides M2 e , HA0, BM2 and a M2 e -BM2 fusion peptide in a composition with a cationic liposome delivery vehicle, and the use of these compositions as a universal vaccine against influenza A and/or B viral strains.
1 . A composition useful for vaccinating a mammalian subject against influenza virus comprising one or more multiple antigenic influenza virus peptides formulated with a cationic liposome delivery vehicle.
2 . A composition useful for vaccinating a mammalian subject against influenza A comprising multiple antigenic peptide M2e conjugated with an cationic liposome delivery vehicle.
3 . The composition of claim 2 wherein the M2e peptide sequence comprises SEQ ID NO: 1.
4 . The composition of claim 2 further comprising multiple antigenic peptide HA0.
5 . The composition of claim 2 further comprising multiple antigenic peptide BM2.
6 . The composition of claim 2 further comprising antigenic peptides HA0 and BM2.
7 . A composition useful for vaccinating a mammalian subject against influenza A comprising a fusion peptide conjugated with a cationic liposome delivery vehicle wherein said fusion peptide comprises an amino acid portion of the M2e peptide and an amino acid portion of the BM2 peptide.
8 . The composition of claim 7 wherein said fusion peptide comprises 10 to 22 amino acids native to the M2e antigenic peptide and 2 to 12 amino acids native to the BM2 antigenic peptide.
9 . The composition of claim 8 wherein said fusion peptide comprises 16 amino acids native to the M2e antigenic peptide and 7 amino acids native to the BM2 antigenic peptide.
10 . The composition of claim 7 wherein the fusion peptide sequence comprises SEQ ID NO: 5.
11 . The composition of claim 7 further comprising antigenic peptides HA0, BM2 and M2e.
12 . A composition useful for vaccinating a mammalian subject against influenza B comprising antigenic peptide BM2 conjugated with a cationic liposome delivery vehicle.
13 . The composition of claim 12 wherein the BM2 peptide sequence comprises SEQ ID NO: 4.
14 . A composition useful for vaccinating a mammalian subject against influenza B comprising a fusion peptide conjugated with an cationic liposome delivery vehicle wherein said fusion peptide comprises an amino acid portion of the M2e peptide and an amino acid portion of the BM2 peptide.
15 . The composition of claim 14 wherein said fusion peptide comprises 10 to 22 amino acids native to the M2e antigenic peptide and 2 to 12 amino acids native to the BM2 antigenic peptide.
16 . The composition of claim 15 wherein said fusion peptide comprises 16 amino acids native to the M2e antigenic peptide and 7 amino acids native to the BM2 antigenic peptide.
17 . The composition of claim 7 wherein the fusion peptide sequence comprises SEQ ID NO: 5.
18 . A method for vaccinating a mammalian subject against influenza virus comprising administering to the subject one or more multiple antigenic influenza virus peptide sequences formulated with a cationic liposome delivery vehicle.
19 . A method for vaccinating a subject against influenza A or influenza B virus comprising administering to the subject a composition comprising one or more peptides selected from M2e, HA0 and BM2, or a M2e-BM2 fusion peptide formulated with a cationic liposome delivery vehicle.
20 . The method of claim 19 wherein said subject is vaccinated against influenza A and said peptide is M2e.
21 . The method of claim 19 wherein said subject is vaccinated against influenza A and said peptides are M2e and HA0.
22 . The method of claim 19 wherein said subject is vaccinated against influenza A and said peptides are M2e, HA0 and BM2.
23 . The method of claim 19 wherein said subject is vaccinated against influenza A and said peptide is HA0.
24 . The method of claim 19 wherein said subject is vaccinated against influenza A and said peptides are HA0 and BM2.
25 . The method of claim 19 wherein said subject is vaccinated against influenza B and said peptide is BM2.
26 . The method of claim 19 wherein said subject is vaccinated against influenza B and said peptides are BM2 and HA0.
27 . The method of claim 19 wherein said subject is vaccinated against influenza B and said peptides are M2e and BM2.
28 . The method of claim 19 wherein said subject is vaccinated against influenza B and said peptides are M2e, HA0 and BM2.
29 . A vaccine composition comprising:
a. cationic liposome delivery vehicle; and
b. one or more peptides selected from the group consisting of:
i. M2e;
ii. HA0;
iii. BM2; and
iv. a M2e-BM2 fusion peptide.
30 . The composition of claim 29 wherein said liposome delivery vehicle comprises lipids selected from the group consisting of multilamellar vesicle lipids and extruded lipids.
31 . The composition of claim 29 wherein said liposome delivery vehicle comprises multilamellar vesicle lipids.
32 . The composition of claim 29 wherein said liposome delivery vehicle comprises pairs of lipids selected from the group consisting of DOTMA and cholesterol; DOTAP and cholesterol; DOTIM and cholesterol; and DDAB and cholesterol.
33 . The composition of claim 32 wherein said liposome delivery vehicle comprises DOTAP and cholesterol.
34 . A method for vaccinating a mammal against influenza comprising administering to said mammal an amount of composition effective to prevent or reduce the effects of the influenza virus, wherein said composition comprises:
a. cationic liposome delivery vehicle; and
b. one or more peptides selected from the group consisting of:
i. M2e;
ii. HA0;
iii. BM2; and
iv. a M2e-BM2 fusion peptide.
35 . The method of claim 34 wherein said liposome delivery vehicle comprises lipids selected from the group consisting of multilamellar vesicle lipids and extruded lipids.
36 . The method of claim 34 wherein said liposome delivery vehicle comprises multilamellar vesicle lipids.
37 . The composition of claim 34 wherein said liposome delivery vehicle comprises pairs of lipids selected from the group consisting of DOTMA and cholesterol; DOTAP and cholesterol; DOTIM and cholesterol; and DDAB and cholesterol.
38 . The composition of claim 37 wherein said liposome delivery vehicle comprises DOTAP and cholesterol.
39 . A composition comprising one or more multiple antigenic influenza virus peptides formulated with a cationic lipid DNA complex.